SYNCOM FORMULATIONS (INDIA)
Back to Balance Sheet
|
SYNCOM FORMULATIONS (INDIA) Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2017 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹12 Cr | ₹10.00 Cr | ₹8.66 Cr | ₹7.76 Cr | ₹7.73 Cr |
What is the latest Total Non-Current Liabilities ratio of SYNCOM FORMULATIONS (INDIA) ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹12 Cr |
| Mar2024 | ₹10.00 Cr |
| Mar2023 | ₹8.66 Cr |
| Mar2022 | ₹7.76 Cr |
| Mar2017 | ₹7.73 Cr |
How is Total Non-Current Liabilities of SYNCOM FORMULATIONS (INDIA) Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹12 Cr | 18.16 | |
| Mar2024 | ₹10.00 Cr | 15.49 | |
| Mar2023 | ₹8.66 Cr | 11.53 | |
| Mar2022 | ₹7.76 Cr | 0.36 | |
| Mar2017 | ₹7.73 Cr | - | |
Compare Total Non-Current Liabilities of peers of SYNCOM FORMULATIONS (INDIA)
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SYNCOM FORMULATIONS (INDIA) | ₹1,347.0 Cr | 3% | 4.1% | -24.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹442,725.0 Cr | -3.2% | 10.5% | 9.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹182,775.0 Cr | 0.8% | 9.5% | 4.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹151,764.0 Cr | 2% | 9.9% | 35.4% | Stock Analytics | |
| CIPLA | ₹113,007.0 Cr | -1.9% | 13.3% | -6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹109,098.0 Cr | -1.8% | 7.4% | 8.2% | Stock Analytics | |
SYNCOM FORMULATIONS (INDIA) Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SYNCOM FORMULATIONS (INDIA) | 3% |
4.1% |
-24.6% |
| SENSEX | 0.2% |
-4.9% |
-8.4% |
You may also like the below Video Courses